Pharmaron Beijing Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Boliang Lou

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentage	n/a
CEO tenure	7.6yrs
CEO ownership	n/a
Management average tenure	7.6yrs
Board average tenure	7.1yrs

Recent management updates

Recent updates

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Mar 04

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Feb 27

CEO Compensation Analysis

How has Boliang Lou's remuneration changed compared to Pharmaron Beijing's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	CN¥1b
Dec 31 2023	n/a	n/a	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥1b
Jan 01 2023	n/a	n/a	CN¥1b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥8m	CN¥2m	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥1b
Dec 31 2020	CN¥4m	CN¥2m	CN¥1b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥865m
Mar 31 2020	n/a	n/a	CN¥594m
Dec 31 2019	CN¥3m	CN¥2m	CN¥547m
Sep 30 2019	n/a	n/a	CN¥437m
Jun 30 2019	n/a	n/a	CN¥378m
Mar 31 2019	n/a	n/a	CN¥346m
Dec 31 2018	CN¥3m	CN¥2m	CN¥333m

Compensation vs Market: Boliang's total compensation ($USD303.85K) is above average for companies of similar size in the CN market ($USD216.73K).

Compensation vs Earnings: Boliang's compensation has been consistent with company performance over the past year.

CEO

Boliang Lou (60 yo)

7.6yrs

Tenure

CN¥2,199,000

Compensation

Dr. Boliang Lou, Ph D serves as Chairman of the Board and Chief Executive Officer at Pharmaron, Inc. He is a Co-Founder at Pharmaron, Inc. Dr. Lou serves as the Chairman, Chief Executive Officer and Manage...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Boliang Lou	Chairman & CEO	no data	CN¥2.20m	no data
Xiaoqiang Lou	Co-Founder	7.6yrs	CN¥1.90m	5.63% CN¥ 1.8b
Shing Chung Li	CFO & Secretary of the Board	no data	CN¥1.96m	no data
Hua Yang	Chief Scientific Officer & Deputy Manager	7.6yrs	CN¥1.85m	no data
Bei Zheng	Executive VP & Executive Director	7.6yrs	CN¥1.65m	3.53% CN¥ 1.1b
Henry Tang	Vice President of Legal Affairs	no data	no data	no data
Connie Sun	Senior VP & Global Head of Business Development of Small Molecules	no data	no data	no data
Celina Zhong	Senior Vice President of Human Resources	no data	no data	no data
Katherine Lee	Chief Business Officer	13.3yrs	no data	no data
Jane Zhang	Chief Quality Officer of Discovery Services	no data	no data	no data
Stephen Lewinton	Senior Vice President of UK Operations	no data	no data	no data
Jingqi Huang	Senior Vice President of In Vivo Pharmacology	no data	no data	no data

7.6yrs

Average Tenure

56yo

Average Age

Experienced Management: 300759's management team is seasoned and experienced (7.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Boliang Lou	Chairman & CEO	7.6yrs	CN¥2.20m	no data
Xiaoqiang Lou	Co-Founder	7.6yrs	CN¥1.90m	5.63% CN¥ 1.8b
Bei Zheng	Executive VP & Executive Director	7.6yrs	CN¥1.65m	3.53% CN¥ 1.1b
Kexin Yang	Chairman of the Supervisory Committee	7.6yrs	no data	no data
Jiaqing Li	Non Executive Director	7.6yrs	no data	no data
Baifeng Hu	Non Executive Director	6.6yrs	no data	no data
Kwan Hung Tsang	Independent Non Executive Director	4.5yrs	CN¥300.00k	no data
Lan Zhang	Employee Representative Supervisor	7.6yrs	no data	no data
Lihua Li	Independent Non Executive Director	1.7yrs	CN¥76.30k	0.0042% CN¥ 1.3m
Jian Yu	Independent Non Executive Director	3.8yrs	CN¥300.00k	no data
Shu Feng	Supervisor	3.4yrs	no data	no data
Qilin Zhou	Independent Non-Executive Director	1.7yrs	CN¥76.30k	no data

7.1yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 300759's board of directors are considered experienced (7.1 years average tenure).

Pharmaron Beijing Management

Management criteria checks 3/4

Key information

Recent management updates

Pharmaron Beijing Co., Ltd. Announces Executive Changes

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

Executive VP & Executive Director recently sold CN¥21m worth of stock

Recent updates

Pharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in 1Q 2023)

Pharmaron Beijing Co., Ltd. Announces Executive Changes

Consensus EPS estimates fall by 14%

Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Price target decreased by 7.3% to CN¥29.29

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 16%

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023

Now 24% undervalued after recent price drop

Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold CN¥231m worth of stock

Executive VP & Executive Director recently sold CN¥22m worth of stock

Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 2Q 2022)

Price target decreased by 8.9% to CN¥35.78

Price target decreased by 9.2% to CN¥36.68

Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023

Price target decreased by 10% to CN¥58.29

President recently sold CN¥13m worth of stock

Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued after recent price drop

Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.21 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 10% to CN¥69.70

Consensus EPS estimates fall by 19%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 10% to CN¥75.56

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2022

Executive VP & Executive Director recently sold CN¥21m worth of stock

President recently sold CN¥31m worth of stock

President recently sold CN¥72m worth of stock

President recently sold CN¥24m worth of stock

President recently sold CN¥41m worth of stock

President recently sold CN¥48m worth of stock

President recently sold CN¥131m worth of stock

Price target decreased to CN¥81.79

Less than half of directors are independent

Price target decreased to CN¥87.07

Price target decreased to CN¥91.49

Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron (Chengdu) Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million.

Third quarter 2022 earnings released

Price target decreased to CN¥94.38

Investor sentiment improved over the past week

Pharmaron Beijing Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Pharmaron Beijing Co., Ltd. Announces Board Appointments

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target decreased to CN¥103

Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 2Q 2021)

Pharmaron Beijing Co., Ltd. Announces Board Changes

Pharmaron Beijing Co., Ltd. to Report First Half, 2022 Results on Aug 29, 2022

Price target increased to CN¥113

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for Period from January 1, 2022 to June 30, 2022

Investor sentiment deteriorated over the past week

Price target decreased to CN¥70.05

Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 14, 2022

Pharmaron Beijing Co., Ltd. Approves Cash Dividend, Payable on 12 July 2022

Pharmaron Beijing Co., Ltd. Approves Cash Dividend

Pharmaron Beijing Co., Ltd. (SZSE:300759) has entered into a definitive Asset Purchase Agreement to acquire Coventry API manufacturing site of Noramco, Inc.

Pharmaron Beijing Co., Ltd. (SZSE:300759) has entered into a definitive Asset Purchase Agreement to acquire Coventry API manufacturing site of Noramco, Inc.

Pharmaron Beijing Co., Ltd. (SZSE:300759) completed the acquisition of 100% equity interest in Beijing Anikeepter Biotech Co from Chen Jing and Chen Xuejun for CNY 85.34 million.

Pharmaron Beijing Co., Ltd., Annual General Meeting, May 31, 2022